Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis.

ABSTRACT:

Importance

Commercial epicutaneous peanut immunotherapy (EPIT) and peanut oral immunotherapy (POIT) may offer significant quality-of-life improvements for patients with peanut allergy, but the cost-effectiveness of commercial peanut immunotherapies is uncharacterized.

Objective

To evaluate critical inputs associated with the cost-effectiveness of EPIT and POIT from a societal perspective.

Design, setting, and participants

Economic evaluation in which microsimulations with Markov modeling were performed evaluating virtual children aged 4 years over an 80-year time horizon. The base-case costs included a caregiver-reported willingness to pay of $3839 annually for safe and effective food allergy treatment. Estimates of predictive biomarkers or oral challenges were incorp

SUBMITTER: Shaker M 

PROVIDER: S-EPMC6503512 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature